Mankind Pharma

Why is Mankind Pharma Ltd falling/rising?

As of 14-Aug, Mankind Pharma Ltd's stock price is rising by 2.0 (0.08%) after a trend reversal, indicating potential recovery in investor sentiment. Despite recent declines, the stock shows strong year-to-date performance at +10.18%, supported by solid fundamentals and high institutional backing.

As of 14-Aug, Mankind Pharma Ltd's stock price is currently rising, as indicated by a change of 2.0 (0.08%) upward. This increase follows a trend reversal after four consecutive days of decline, suggesting a potential recovery in investor sentiment. Additionally, the stock has outperformed its sector by 0.94% today, which may contribute to the positive movement in its price.<BR><BR>Despite a recent decline over the past week (-0.78%) and month (-4.37%), the year-to-date performance remains strong at +10.18%, indicating overall resilience in the stock's performance. The company's fundamentals also support this rise, with high management efficiency reflected in a return on capital employed (ROCE) of 20.79% and a low debt to EBITDA ratio of 1.74 times, showcasing a strong ability to service debt.<BR><BR>Moreover, the company has demonstrated healthy long-term growth, with net sales growing at an annual rate of 17.23% and operating profit at 18.48%. Positive financial results reported for the latest period, including an operating cash flow of Rs 2,751.99 Cr and a significant growth in profit after tax, further bolster investor confidence.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 73.19% against the 5-day average, which could indicate caution among some investors. Nonetheless, the high institutional holdings at 24.84% suggest that more knowledgeable investors are backing the stock, which may provide additional support for its price movement. Overall, the combination of a recent upward trend, strong fundamentals, and institutional backing contributes to the rising price of Mankind Pharma Ltd.

Which are the latest news on Mankind Pharma?

Who are in the management team of Mankind Pharma?

The management team of Mankind Pharma includes Ramesh Chand Juneja (Chairman), Rajeev Juneja (Vice Chairman & Managing Director), Sheetal Arora (CEO), and several independent directors, among others, who collectively guide the company's strategic direction and operations.

The management team of Mankind Pharma includes the following key individuals:<BR><BR>1. **Ramesh Chand Juneja** - Chairman & Wholetime Director<BR>2. **Rajeev Juneja** - Vice Chairman & Managing Director<BR>3. **Sheetal Arora** - Whole Time Director & CEO<BR>4. **Tilokchand Punamchand Ostwal** - Independent Director<BR>5. **Pradeep Chugh** - Company Secretary & Compliance Officer<BR>6. **Bharat Anand** - Independent Director<BR>7. **Satish Kumar Sharma** - Whole-time Director<BR>8. **Vivek Kalra** - Independent Director<BR>9. **Vijaya Sampath** - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

What does Mankind Pharma do?

Mankind Pharma Ltd is a mid-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of ₹4,031 Cr and a net profit of ₹568 Cr for June 2026. Key financial metrics include a P/E ratio of 46.00 and a debt-equity ratio of 0.26.

Overview: <BR>Mankind Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History: <BR>Mankind Pharma Limited was incorporated in 1991 as a Private Limited Company and later converted to a Public Limited Company in 2005. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 4,031 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 568 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 100,034 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 46.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.26 <BR>Return on Equity: 12.39% <BR>Price to Book: 6.14 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Mankind Pharma?

Mankind Pharma's peers include Divi's Lab, Torrent Pharma, Cipla, Zydus Lifesciences, Lupin, Laurus Labs, Dr Reddy's Labs, Aurobindo Pharma, Biocon, and Alkem Lab. Mankind Pharma shows good growth and an excellent capital structure, with a 1-year return of -1.93%.

Peers: The peers of Mankind Pharma are Divi's Lab., Torrent Pharma, Cipla, Zydus Lifesci., Lupin, Laurus Labs, Dr Reddy's Labs, Aurobindo Pharma, Biocon, and Alkem Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Divi's Lab., Torrent Pharma, Cipla, Zydus Lifesci., Lupin, Mankind Pharma, Laurus Labs, Dr Reddy's Labs, and Alkem Lab., while Average management risk is found at Aurobindo Pharma and Biocon. Growth is excellent at Zydus Lifesci. and Lupin, while good growth is noted for Mankind Pharma. Below average growth is seen at Divi's Lab., Cipla, Laurus Labs, and Alkem Lab., and the rest have average growth. Excellent capital structure is noted for Divi's Lab., Cipla, Zydus Lifesci., Mankind Pharma, Dr Reddy's Labs, and Aurobindo Pharma, while average capital structure is found at Laurus Labs and below average at Biocon.<BR><BR>Return Snapshot: Laurus Labs has the highest 1-year return at 113.22%, while Cipla has the lowest at -6.46%. Mankind Pharma's 1-year return is -1.93%, which is higher than Cipla's but lower than Laurus Labs. Additionally, Dr Reddy's Labs and Biocon have negative six-month returns.

How big is Mankind Pharma?

As of 14th August, Mankind Pharma Ltd has a market capitalization of 99,825.26 Cr, with recent net sales of 14,737.88 Cr and a net profit of 2,042.67 Cr.

As of 14th August, Mankind Pharma Ltd has a market capitalization of 99,825.26 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest 4 quarters, Mankind Pharma reported Net Sales of 14,737.88 Cr and a Net Profit of 2,042.67 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, with Shareholder's Funds amounting to 16,300.34 Cr and Total Assets valued at 27,754.83 Cr.

Should I buy, sell or hold Mankind Pharma Ltd?

Are Mankind Pharma Ltd latest results good or bad?

Mankind Pharma Ltd's latest results show strong revenue growth, with net sales reaching ₹4,030.59 crores, a 17.07% increase sequentially and 12.89% year-on-year. However, declining operating and PAT margins due to rising costs raise concerns about sustainability in a competitive market.

Mankind Pharma Ltd's latest results present a mixed picture. On the positive side, the company achieved a significant milestone with net sales reaching ₹4,030.59 crores, marking a 17.07% sequential growth and a 12.89% increase year-on-year. This is the highest quarterly revenue in the company's history, indicating strong demand across its product portfolio.<BR><BR>Net profit also showed a positive trend, increasing by 2.47% quarter-on-quarter to ₹568.06 crores, and a notable 29.60% year-on-year growth. However, despite these impressive revenue and profit figures, the company faced challenges with margin compression. The operating margin decreased to 26.20%, down 81 basis points from the previous quarter, and the PAT margin contracted to 14.24%, reflecting rising costs, particularly in employee expenses.<BR><BR>Overall, while Mankind Pharma's revenue growth is commendable and demonstrates operational resilience, the declining margins raise concerns about sustainability in an increasingly competitive market. Investors may need to monitor how the company addresses these margin pressures moving forward.

When is the next results date for Mankind Pharma Ltd?

The next results date for Mankind Pharma Ltd is 30 July 2026.

The next results date for Mankind Pharma Ltd is scheduled for 30 July 2026.

Is Mankind Pharma technically bullish or bearish?

As of December 1, 2025, the technical trend has shifted to a bearish stance, driven by bearish MACD and Bollinger Bands signals, despite a bullish weekly RSI, with the stock trading below its previous close and well off its 52-week high.

As of 1 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands on both weekly and monthly timeframes, and a bearish moving average on the daily timeframe. The weekly RSI is bullish, but this is overshadowed by the overall bearish trend in other indicators. The KST is mildly bearish, and there is no clear trend indicated by Dow Theory or OBV. Overall, the bearish sentiment is reinforced by the recent price action, with the stock trading below its previous close and significantly off its 52-week high.

How has been the historical performance of Mankind Pharma?

Mankind Pharma has shown consistent growth, with net sales increasing from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025, alongside rising profits and improved cash flow. Total assets surged from INR 6,323.62 crore to INR 27,651.64 crore during the same period.

Answer:<BR>The historical performance of Mankind Pharma shows a consistent growth trajectory in net sales and profits over the years.<BR><BR>Breakdown:<BR>Mankind Pharma's net sales have increased significantly from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025. This growth is reflected in the total operating income, which rose from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025. The total expenditure, excluding depreciation, also grew from INR 4,566.33 crore in March 2021 to INR 9,189.51 crore in March 2025, indicating rising operational costs. Operating profit (PBDIT) has shown a positive trend, climbing from INR 1,819.05 crore in March 2021 to INR 3,554.72 crore in March 2025. Profit before tax increased from INR 1,679.93 crore in March 2021 to INR 2,504.09 crore in March 2025, while profit after tax rose from INR 1,281.35 crore to INR 1,994.35 crore during the same period. The company's total assets surged from INR 6,323.62 crore in March 2021 to INR 27,651.64 crore in March 2025, with total liabilities also increasing from INR 6,323.62 crore to INR 8,483.03 crore. The cash flow from operating activities improved from INR 1,137 crore in March 2021 to INR 2,413 crore in March 2025, reflecting enhanced operational efficiency. Overall, Mankind Pharma has demonstrated robust growth in revenue and profitability, alongside a significant increase in assets and cash flow.

Is Mankind Pharma overvalued or undervalued?

As of October 13, 2025, Mankind Pharma is considered very expensive with a PE ratio of 53.30 and significant underperformance compared to peers and the Sensex, indicating it may be overvalued.

As of 13 October 2025, Mankind Pharma's valuation grade has moved from expensive to very expensive, indicating a significant shift in its market perception. The company appears to be overvalued based on key financial ratios, including a PE ratio of 53.30, an EV to EBITDA of 33.50, and a Price to Book Value of 7.06. These figures suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Mankind Pharma's valuation stands out as particularly high; for instance, Sun Pharma has a PE ratio of 34.9, while Cipla is valued attractively with a PE of 23.43. The disparity in valuations raises concerns about Mankind's sustainability at these levels. Furthermore, the company's stock has underperformed against the Sensex, with a year-to-date return of -15.1% compared to the Sensex's gain of 5.36%. This underperformance further supports the conclusion that Mankind Pharma is currently overvalued.

Who are the top shareholders of the Mankind Pharma?

The top shareholder of Mankind Pharma is the Ramesh Juneja Family Trust, holding 20.2%. Promoters own the majority, with institutional investors holding 20.59% combined, while individual investors own about 1.64%.

The top shareholders of Mankind Pharma include the Ramesh Juneja Family Trust, which holds the largest stake at 20.2%. The company is primarily owned by its promoters, with no pledged promoter holdings reported. Additionally, institutional investors are involved, with 32 mutual fund schemes holding a combined 7.67% and 554 foreign institutional investors (FIIs) holding 12.92%. The highest public shareholder is the SBI Large & Midcap Fund, which holds 1.58%. Individual investors collectively own about 1.64% of the company.

Has Mankind Pharma declared dividend?

No Dividend History Available